Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with
three approved products for B-cell malignancies and a large pipeline of treatments in clinical …

Oncolytic viruses (OVs) encoding a variety of transgenes have been evaluated as
therapeutic tools to increase the efficacy of chimeric antigen receptor (CAR)–modified T cells …

Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …

Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Chimeric antigen receptor (CAR)–T cells have shown efficacy in patients with B cell
malignancies. Yet, their application for solid tumors has challenges that include limited …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

Chimeric antigen receptor–T cell (CAR-T) therapy has been effective in the treatment of
hematologic malignancies, but it has shown limited efficacy against solid tumors. Here we …

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …